Company intelligence / Profile preview

NovoTek Pharmaceuticals

United States

Ownership: Private
Development stage: Other

Overview

Clinical trials conducted in 2021 demonstrated that NP-101 has applications for immunotherapy and cancer treatment, showcasing significant effects on T cells.[1] The company initiated a randomized, double-blinded, placebo-controlled Phase 2 study of NP-101 against COVID-19 in the outpatient setting.[1]

Therapeutic areas: OncologyInfectious Diseases
Modalities: Herbal medicineSmall molecule
Industry: Biotech

Partnerships

Case Western Reserve University School of Medicine

Beyond the preview

Go deeper on NovoTek Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NovoTek Pharmaceuticals.

Explore the full profile